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Aim: Previously, we reported that visual arrestin co-puriﬁed with glycolytic enzymes. The aim of this
study was to analyze the co-puriﬁcation of arrestin like proteins (ALP) in bovine cardiac tissues with
enolases.
Methods: The soluble extract of bovine myocardial tissues from different regions such as left and right
atriums and ventricles of the bovine heart (n ¼ 3) was analyzed by ACA-34 gel ﬁltration, immuno-afﬁnity
column, SDS-PAGE, ELISA, western blot and a sandwich immune assay for quantiﬁcation of ALP and
sequence analysis.
Results: We observed that; 1) The cardiac muscle contained a 50 kDa ALP at a concentration of 751 pg/
mg of soluble protein extract, 2) ALP puriﬁed, by immunoafﬁnity, contained alpha-enolase of 48 kDa
conﬁrmed by protein sequence analysis; 3) Cardiomyocyte cells exposed to anti arrestin and anti enolase
monoclonal antibodies showed decreased proliferation in vitro, 4) High level of autoantibodies were
detected by ELISA (3.57% for arrestin and 9.12% for a-enolase) in serum of patients with infarcted heart
disease.
Conclusion: We suggest a possible interaction between ALP and alpha-enolases yielding a complex that
may be involved in the induction of cardiac autoimmune diseases.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Arrestins play a central role in desensitization of G-protein-
coupled receptors (GPCRs) [1,2]. G protein coupled receptors
(GPCRs) use two major signaling mechanisms, one mediated
through the classical activation of G-proteins and the other through
the activation of b arrestins [3]. b arrestin, in addition to receptor
desensitization, is involved in receptor endocytosis, activation of
extracellular signal regulated kinases (ERK) and other mitogen
activated protein (MAP) kinases [4]. b arrestin which is an isoform
of arrestin, form complexes with several signaling proteins,
including Src family tyrosine kinases and components of the ERK1/
2 and JNK3 MAP kinase cascades [1]. We and others have shown
that immunization of mammals by arrestin (S-antigen) as an auto, INSERM U965, Carcinose,
l Lariboisiere, 41 Bd de la
Mirshahi).
Inc. This is an open access article uantigen induces experimental uveitis [5]. Cardiac muscle cells
harbor an important family of surface protein receptors GPCRs
which enables cells to sense and respond to outside signals [6].
Another protein, enolase, is a glycolytic cytoplasmic enzyme,
known to be a multifunctional and cell membrane a-enolase has
been identiﬁed as plasminogen receptor (PR) [7]. Wound healing
after infarct failed in plasminogen-deﬁcient mice, indicating that
the plasminogen-R system is required for the repair process of the
heart post infarction [8]. In in vitro studies, a-enolase was found
necessary for regeneration of normal and dystrophic skeletal
muscles [9]. In rat, a-enolase was found to be strongly induced in
response to ischemic hypoxia [10], it has therefore been proposed
as a marker for early diagnosis of acute myocardial infarction [11].
A few years back, we had reported that bovine visual arrestin co-
puriﬁed with selected glycolytic enzymes such as a and g enolase,
aspartate aminotransferase and glucose-6-phosphate isomerase
[12]. We had also demonstrated the presence of arrestin likes
proteins (ALP) in cardiac tissues [13]. In the present work, we show
using (anti visual arrestin speciﬁc monoclonal antibodies immu-
noafﬁnity column), that ALP from bovine cardiac muscle extractsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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visual arrestin in uveitis and arrestin-enolase in neuronal tissues as
auto antigens [14], the serum from patients with heart diseases
were tested for the presence of auoantibodies against both these
proteins. Since these proteins may be involved in the induction of
cardiac autoimmune diseases.
2. Materials and method
2.1. Antigen and antibodies
Visual S-antigen (arrestin) was puriﬁed from bovine retina as
described [15] Polyclonal anti arrestin was prepared by injecting
rabbits with 200 mg of protein emulsiﬁed in complete Freund's
adjuvant [5]. Several mouse and rat monoclonal antibodies (mAbs)
against retinal arrestin were produced [16] and characterized by
epitope mapping employing combinations of two methods,
namely, overlapping of synthetic peptides and petscan analysis as
described previously [17]. Antibodies S8D8 (mouse IgG2a aa
40e50), S9E2 (mouse IgG2a, aa 361e368) and rat mAb M1E5 (rat
IgG1, aa 279e306) were produced as previously reported [16,18].
On western blot of crude extracts from mammalian retinas, these
mAbs reacted with a single band of 48 kDa. Monoclonal anti
enolase (PR11G-1 IgG1) was retired in our laboratory by immuni-
zation of mouse using MCF-7 breast adenocarcinoma cell line, as
previously described [19]. E1A3 another anti enolase produced
when mouse anti-retinal arrestin were prepared. All anti enolase
antibodies reacted with puriﬁed enolase and recognized a band at
48 kDa in western blots.
2.2. Bovine myocardial tissue extracts
Crude soluble extracts were prepared according to the following
procedure. Myocardial tissues from fresh bovine hearts were
dissected free from endocardial tissues. Pooled myocardial tissues
or left/right atriums and left/right ventricles were prepared sepa-
rately. Seventy grams of tissues were homogenized at þ4 C in
presence of antiprotease phenylethylsoufonyl ﬂuoride with an Ul-
tra turrax tissue grinder in 140 mL of ice-cold hypotonic 10 mM
phosphate buffer, pH 7.4. It was then centrifuged at 27  103 g for
30 min at 4 C. We prepared 12 different myocardium soluble ex-
tracts (see Table 1) from which arrestin like proteins were
quantiﬁed.
2.3. Puriﬁcation of heart arrestin like proteins (ALP)
An equal volume of saturated ammonium sulfate was added to
the crude extracts described above. The resulting precipitate was
dissolved In 10 mM phosphate buffer solution (PBS), pH 7.4, dia-
lyzed against PBS, centrifuged and fractionated by gel ﬁltration on
an ultrogel ACA-34 (SigmaeAldrich, France) column. The fraction
containing immunoreactive protein detected by ELISA were pooled
and passed through monoclonal anti retinal arrestin antibody
(S8D8) immunoafﬁnity Column. The bound material was eluted
with 5M Tris, 5M urea buffer, pH 9.5 and dialyzed against PBS, pH
7.4. They were than tested in an ELISA using the rabbit anti arrestin
antibody and monoclonal anti arrestin antibodies. The positive
fractions were pooled and concentrated under vacuum. Protein
characterization was performed by gel electrophoresis. The same
method was used to purify the immunoreactive proteins of the
cardiac soluble extract using columns of immobilized rabbit anti
arrestin antibody. In this experiment the bound material was des-
orbed by 200 mM glycine-HCL buffer, pH 2.5, at 4 C and the eluted
fractions were immediately neutralized using 2M Tris the puriﬁedfraction were analyzed by electrophoresed for 4 h in a 15%
acrylamide.
2.4. Quantiﬁcation of arrestin like protein
Monoclonal anti arrestin (S8D8) was used as solid phase (cap-
ture antibody) and rabbit polyclonal antibodies as conjugates
(enzymatic tracer). Conjugates were prepared by coupling the
tetrameric form of the acetylcholinesterase enzyme (ACHE) (EC 3.1.
1. 7 from electrophorus electricus, G4 form) with antibody. 96 well
microplates were coated with S8D8 (10 mg/ml) overnight at 4 C in
sodium bicarbonat bufferePhosphat buffer (PH 9.5). After 3 washes
with PBS the plates were reacted either with bovine standard
retinal arrestin in 0.01M sodium phosphate buffer, pH 7.0, con-
taining 0.10% BSA, or with different myocardium extracts diluted in
the same buffer together with the enzymatic conjugate after
overnight immunoreactions at 4 C. Plates were washed and
immobilized AChE activity was measured as described [20]. Protein
determination was performed by Bradford technique.
2.5. Western blot
Proteins of immunopositive fractions were denatured in
220 mM TriseHCl buffer, pH 6.0, with 2% SDS, 15% glycerol and
electrophoresed for 4 h in a 10e20% acrylamide gradient gel and
then electrotransferred to nitrocellulose membranes (Millipore,
Bedford, MA) for 1 h in 0.15% TriseHCl, 0.72% glycine, 20M (v/v)
methanol. The membrane was incubated with (5 mg/ml) polyclonal
or monoclonal antibodies followed by their detection with bio-
tinylated goat anti-rabbit or sheep anti-mouse. A series of stan-
dards (Bio-rad, France) were used as molecular mass.
2.6. Sequence analysis
was performed as previously described [12]. Brieﬂy, Following
SDS-PAG and electroblotting, of puriﬁed arrestin like protein by
S8S8 monoclonal anti arrestin antibody, the blotted spot, 48 and
50 kDa, were cut into small pieces and triyptic digestion was per-
formed according Aebersold [21]. The resulting peptides were
separated by revers phase HPLC followed by acetonitrile. Sequence
determination was performed by Edman degradation [22] with an
Applid Biosystem 473 sequencer [23] and the sequences were
compared with those in the NBRF bank, using the FASTA program.
2.7. ELISA
ELISA was performed for detection of arrestin and enolase
immunoreactivity in all fraction of chromatography as described in
[12]. In order to determine the role of the serum anti arrestin/
enolase as a possible indicator in heart autoimmunity, we con-
ducted a retrospective study on 157 patients with myocardial in-
farcts (from Pitie-Salpe^triere University Hospital, Paris, France, Pr. J.
P Collet). The detection of auto antibodies by ELISA, against target
proteins used 0.2 mL of plasma for each patient.
2.8. Cell proliferation
3000 myocardial cells (H9C2; rat cell line) in DMEM com-
plemented by 10% calf fetal serumwas plated in E-plate 96 (Roche,
San Diego, USA) and placed in a wet xCELLigence apparatus (Roche,
France) at 37 C, 5% CO2 for real time cell proliferation assay. After
48 h, the cells in E-plate were treated with a fresh complete DMEM
medium containing 5-mg of different monoclonal antibodies (anti
arrestin and anti enolase). The xCELLigence System measures
electrical impedance across interdigitated micro-electrodes
Table 1
Quantiﬁcation of arrestin like proteins in the 4 regions of the heart. In the 4 regions
of the heart such as left and right atriums and ventricles of the 3 bovine hearts,
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cellular events in real time without the incorporation of labels.soluble extract contained 13.6 ng/ml (46.83e2.02 ng/ml) of arrestin like proteins per
18.1 mg/ml (21.6e12 mg/ml) of soluble extract (ratio 1/1330). The data suggest that
the cardiac muscle contained arrestin like protein at a concentration of 751 pg/mg of
soluble extract protein.
Cardiac muscle extract Total protein mg/ml Arrestin like proteins ng/ml
RA1 15.61 ± 2.93 3.58 ± 0.44
RA2 14.96 ± 3.17 8.05 ± 0.57
RA3 18.53 ± 4.32 18.79 ± 3.15
LA1 19.29 ± 4.21 46.83 ± 8.56
LA2 21.60 ± 4.57 16.83 ± 2.84
LA3 18.31 3.16 4.07 ± 0.53
RV1 18.95 ± 3.77 5.91 ± 0.77
RV2 18.87 ± 2.94 11.40 ± 1.21
RV3 15.57 ± 3.62 26.86 ± 3.24
LV1 18.42 ± 3.14 2.02 ± 1.22
LV2 18.49 ± 3.71 2.88 ± 041
LV3 18.50 ± 3.26 17.49 ± 3.62
RA pool 17.72 ± 3.31 9.94 ± 1.22
LA pool 18.70 ± 3.20 19.93 ± 4493
Rv pool 19.64 ± 4.17 13.82 ± 3.08
Lv pool 16.63 ± 3.54 7.87 ± 0.863. Results
3.1. Bovine myocardial tissues extracts contain arrestin like proteins
Fig. 1A shows the gel ﬁltration proﬁle of soluble proteins from
myocardium. A series of fractions reacted positively giving a major
pick in ELISA against monoclonal antibody S8D8 (Peak A, fractions
58e76). Crude tissue extract showed a weak immunoreactivity
with antibodies to retinal arrestin (results not shown). The pooled
peak “A” from gel ﬁltration was passed through an immunoafﬁnity
column of S8D8 Mab (Fig. 1B). Fig. 1C shows the SDS-Page analysis
of pooled fractions from Peak A of crude myocardial extracts (C-1),
hydroxyl apatite puriﬁed bovine visual arrestin of 48 kDa (C-2) and
Immunopuriﬁed (fractions 41e55) using rabbit anti arrestin revels
an arrestin band of superior molecular weight, 50 kDa as compared
to visual arrestin (C-3). Fig. 1C (C-4) shows western blot analysis of
pooled fractions 41-55 from immunoafﬁnity column with S8D8
Mab compared with the control (F1E1 mab) presented in Fig. 1C (C-
5). The four monoclonal anti arrestin antibodies (S2D2, S8D8,
M1E5, S9E2) reacted positively by ELISA with pooled fractions 41-
55 as compared to the control antibody (F1E1).3.2. Quantiﬁcation of ALP in soluble extracts of bovine myocardium
In the 4 regions of bovine hearts (n ¼ 3) such as left and right
atriums and ventricles, arrestin like proteins were detected. As
presented in Table 1, the total protein concentrations of all extracts
were comparable irrespective of which region of the heart and that
to all the three hearts. The concentration of immunoreactive pro-
teins in the crude myocardium soluble extracts was approximately
0.75 mg per gram of protein. The soluble extract contained 13.6 ng/
ml of arrestin like proteins per 18.1 mg/ml of soluble extract (ratio
1/1330). Conversely, there was a large variation in the amount of
arrestin like immunoreactive proteins between the fourFig. 1. The soluble extract of bovine's myocardial tissues analysis. A: The soluble extrac
immunoreactivity reveled using anti arrestin antibody, A major peak (peak a, fractions of 61
the fraction of 41e55 contained ALP. C: SDS-PAG analysis of all fraction Myocardial extracts (a
arrestin (c) and using S8D8 monoclonal antibody (d). A 50 kDa arrestin like proteins puriﬁed
analysis of immunopuriﬁed heart ALP by several monoclonal antibodies to retinal arrestin.compartments of the same heart, ranging from 0.11 to 2.43 mg/g
proteins for a given compartment in the three hearts.
3.3. Co-puriﬁcation of ALP with a-enolase
Western blot analysis of the ALP, immune-puriﬁed from the
soluble extract of myocardial tissues fractions of ACA-34 gel
ﬁltration, contained ALP immunoreactivity. The results conﬁrm the
presence of a 50 kDa protein that reacts with anti arrestin (S8D8
Mab, Fig. 2A,1) anti a-enolase (PR-11G1 Mab, Fig. 2A, 2), polyclonal
rat anti-bovine heart anti-ALP (Fig. 2A, 3). It reveals a double band
corresponding to 50 and 48 kDa representing arrestin and its co-
puriﬁed protein, a-enolase. Similar results were obtained with
the fractions retained by immunoafﬁnity using other anti arrestint of bovine's myocardial tissues analyzed by ACA-34 gel ﬁltration and arrestin like
e76) contain arrestin like protein. B: Peak a analyzed by S8D8 immunoafﬁnity column,
) HA puriﬁed arrestin (b), Immunopuriﬁed heart ALP by immunoafﬁnity by a rabbit anti
from myocardium soluble extract by anti arrestin antibodies (SDS-PAGE 10%). D: ElISA
Fig. 2. Cross reaction of anti arrestin and anti a-enolase monoclonal antibodies with
cardiac arrestin puriﬁed by S8D8 immunoafﬁnity. A: by anti arrestin (a), anti enolase
(b) and rat anti heart ALP (C). B: Elisa using rat anti arresti, S2D2 (anti arrestin), E1A3,
PR11G1 (anti enolase) and F1E1a monoclonal antibody to ﬁbrinogen (control).
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arrestin (results not shown). These results were conﬁrmed when
ALP from immunoafﬁnity column was tested in ELISA with several
antibodies against visual arrestin (S2D2), and monoclonal anti a-
enolase antibodies (E1A3 and PR11G1) (Fig. 2B). F1E1 an anti-
human ﬁbrinogen, was used as control.3.4. Sequences analysis
Structural analysis of two tryptic digest proteins (Table 2)
reveled four peptides for 48 kDa, and 3 for 50 kDa proteins with the
following sequences: The peptides (KLMIEMDGT), (LAMQEFM),
(KNVIKEK) and (VVGLCTGQIK) were identiﬁed for 48 kDa band and
(KRDFVDHI), (KLKHEDTNLA) and (GDLSSD) for 50 kDa band. TheseTable 2
Sequences analysis of trypsin depredate products of 50 kDa and 48 kDa bands. Three
peptides (F1 to F3) in digested 50 KDa protein reveled the strict homology b arrestin
family(A) and four peptides (F1 o F4) in digested 50 KDa protein reveled the strict
homology with a-enolase.
A
Trypsin depredate products of 50 kDa Polypeptide sequences
F-1
b arrestin
KRDFVDHI
24-KRDFVDHI-33
F-2
b arrestin
KLKHEDTNLA
291-KLKHEDTNLA-301
F-3
b arrestin
GDLSSD
336-GDLSSD-343
B
Trypsin depredate products of 48 kDa Polypeptide sequences
F-1
a-enolase
KLMIEMDGT
91-KLMIEMDGT-101
F-2
a-enolase
LAMQEFM
163-LAMQEFM-171
F-3
a-enolase
KNVIKEK
193-KNVIKEK-201
F-3
a-enolase
VVGLCTGQIK
285-VVGLCTGQIK -296results conﬁrm that using anti-pan arrestin monoclonal antibodies
for puriﬁcation of arrestin, enolase will be co-puriﬁed with ALP.
3.5. The effect of antibodies against arrestin and enolase on
cardiomyocyte cell proliferation
The proliferations of cells during 48 h after elimination of an-
tibodies from culture media were measured using xCELLigence
apparatus and the results presented as cell (proliferation index) in
Fig. 3. Fig. 3 shows the myocardyocyte proliferation in culture
(control). This proliferation was affected when anti arrestin S8D8
(epitope localized in N-terminal) or S9E2 (epitope localized in C-
terminal) or anti enolase PR11G-1 was added to the culture me-
dium. Using xCELLigence system, reveled information during the
progression of the experiments will be recorded and known in real
time.
3.6. Autoantibody detection against of the arrestins and the
enolases in patients with heart disease
The serums of patients with the coronary heart disease were
tested for detection of auto antibodies against retinal arrestin and
a-enolase. High level of autoantibodies was found in some of the
patients tested against of bovine retinal arrestin and a-enolase
(Table 3). The immunoractivity of serumwith the proteins in ELISA,
divided the patients in four categories: category A- 9.12% serum
contained antibodies against a-enolase, category B- 3.57% serum
contained antibodies against arrestin, category-C 1.9% serum con-
tained antibodies against arrestin and a-enolase and category-D
85.4% absence of immunoreactivity. These results point out that
auto antigen are detectable by ELISA in human cardiac infarcts.
4. Discussion
Arrestin like proteins from the bovine myocardium soluble ex-
tracts were puriﬁed by immune afﬁnity columns using a mono-
clonal antibody that recognized an epitope presented in all
members of arrestin family (40-50 aa epitope in bovine visual
arrestin). Eluted proteins comprised 2 proteins components with
molecular weights of 48 and 50 kDa. As veriﬁed by western blot,
ELISA, and protein sequencing, the 48 kDa turn out to be the alpha-
enolase and the 50 kDa as arrestin. This result indicated that,
arrestin family was completed with enolase in the heart muscles.Fig. 3. The effect of antibodies on the rat cardiomyocyte cell line proliferation. 5 ug/ml
of monoclonal antibodies; anti-arrestin S8D8 (anti N-terminal), anti-arrestin S9E2
(anti C-terminal), anti-enolase PR11G1 were added in culture medium for 48 h. The
real time proliferations of the cells during 48 h after elimination of antibodies from
culture media were measured using xCELLigence apparatus and results presented as
cell (proliferation) index.
Table 3
The immunoractivity of serumwith the proteins, bovine visual arrestin and rabbit a-
enolase in ELISA were different according to patients. group A, serum contained
antibodies against arrestin, group B, serum contained antibodies against a-enolase,
group C, serum contained antibodies against arrestin and a-enolase and group D,
absence of immunoreactivity.
Patients Arrestin (OD 482 nm) Enolase (OD 482 nm)
A (3.57%)
301 1191 0.150
241 1628 0.137
B (9.12%)
281 0.042 0.885
213 0.255 0.996
C (1.9%)
320 0.799 0.568
47 0.615 0.650
D (85.4%)
323 0.044 0.033
335 0.051 0.097
M. Mirshahi, S. Le Marchand / Biochemical and Biophysical Research Communications 460 (2015) 657e662 661Arrestin and a-enolase are cytosolic proteins, whereas the
membrane associated enolase, described earlier by our group [24]
and by other authors, as plasminogen-receptors [24,25] The
occurrence of arrestin in themembrane bound form on the external
cell surface is not so far documented.
The bovine heart (consisting of the four regions left and right
atriums and left and right ventricles) contained 13.6 ng/ml of
arrestin like proteins per 18.1 mg/ml of soluble extract (ratio 1/
1330). The data indicates that bovine cardiac muscles contain
arrestin like protein at a concentration of 751 pg/mg of total soluble
protein extract. Since we are looking at soluble heart protein ex-
tracts, this study conﬁnes itself to only free cytosolic arrestin. The
content of arrestin varies in the four different regions of the heart.Fig. 4. a schema for describe pathologic events in that arresti-enolase complex. In norma
phorylation that ensues [3], arrestin couples with the phosphorylated amino acid residues [
detaches from arrestin by phosphatase action [4,5] and the freed receptor, along with a frag
phosphatase activity may undergo diminution under pathological conditions (A), in which ca
suggest that arrestin like proteins can associate with a-enolase and this pair can appear onSurprisingly, left atrium (LA) and right ventricle (RV) cardiac
muscles contain more soluble arrestin (free) compared to right
atrium (RA) and left ventricle (LV) (Table 1). The membrane bound
arrestin present in RA and LV are not available for evaluation.
From the data generated In this study we are tempted to spec-
ulate that in pathologic condition, arrestin (and enolase)- no
resensitizated GPCRs complex can be externalized as an auto-
antigen on the cardiomyocyte membrane which could result in the
induction of autoantibodies (Fig. 4C).
We had demonstrated earlier the co-puriﬁcation of visual
arrestin with glycolytic enzyme such as a and g enolase, aspartate
aminotransferase and glucose-6-phosphate isomerase [12].
Enolase, also known as phosphopyruvate hydratase, is one of the
most abundantly expressed cytosolic proteins in many organisms.
It is a metallo-enzyme that requires the magnesium ions (Mg2þ) for
its catalytic activity [26]. Three isoforms of enolase; a-enolase
present in all tissues, b-enolase present in muscles and g-enolase in
neurons were described in all vertebrate. Tissue speciﬁc isozymes
of enolase (b and g) readily form mixed hetro dimers with a-
enolase [26]. In this study, we observed the interaction of arrestin
like proteins only with a-enolase. Whether, or not, b and g enolases
also interact with heart arrestins remains yet to be demonstrated.
Serum from patients with the heart disease was tested for the
presence of arrestin-enolase auoantibodies. We tested by ELISA the
serum of 157 infarcted heart diseases, and found a high level of
autoantibodies (3.57% for arrestin and 9.12% for a-enolase)
compared with other serum. The relation between the autoanti-
bodies detected and heart disease could not be clariﬁed. Though all
the sera came from infarct cases the distinctive features of indi-
vidual samples could not be taken into account. It remains to be
seenwhether these antibodies are disease speciﬁc. The appearance
of autoantibodies would have deleterious effect on cardiac cells.l situation, following agonist association/interaction with GPCRs [1e7], and the phos-
3]. As a result the complex of receptor-agonist internalization [4] and then the receptor
ment of the membrane, returns and fuses with the cell membrane (Fig-6,7] [1,29]. The
se the epitopes linking the arrestin-enolase couple is externalized (B). The present data
the surface of the cell membranes as auto antigen (C).
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clonal antibodies against arrestin or enolase. Such a treatment
resulted in noticeable decrease in cell proliferation, suggesting the
presence of arrestin and enolase epitops onmembranes of live cells.
This phenomenon can be produced by down regulation of phos-
phatase activity under pathological conditions including cell stress
that abolish GPCRs resensitization [27,28].
For describe pathologic events in that arrestin-enolase complex
were exposed on the cell membrane, we proposed a modiﬁed
classic schema [1,29]. In normal situation, following agonist asso-
ciation/interaction with GPCRs (Fig. 4, 1e7), and the phosphoryla-
tion that ensues (Fig. 4-3), arrestin couples with the
phosphorylated a mino acid residues (Fig. 4-3). As a result the
complex of receptor-agonist internalization (Fig. 4-4) and then the
receptor detaches from arrestin by phosphatase action (Fig. 4-4,5)
and the freed receptor, along with a fragment of the membrane,
returns and fuses with the cell membrane (Fig. 4-6, 7). The phos-
phatase activity may undergo diminution under pathological con-
ditions (Fig. 4A), in which case the epitopes linking the arrestin-
enolase couple is externalized (Fig. 4B). The present data suggest
that arrestin like proteins can associate with a-enolase and this pair
can appear on the surface of the cell membranes as auto antigen
(Fig. 4C). This association may be inﬂuence the signal transduction
by membrane GPCRs as well as the glycolytic pathway in cardiac
muscles.
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